Target intelligence / Profile preview

Puumala virus Gn glycoprotein (Gn)

Target
Gn
Molecular classification
Viral envelope glycoprotein, Type I transmembrane protein
01

Overview

The Puumala virus Gn glycoprotein is a critical surface-exposed protein of the Puumala orthohantavirus, which is the primary causative agent of Nephropathia epidemica, a form of hemorrhagic fever with renal syndrome (HFRS) (Vaheri et al., 2013, Nature Reviews Microbiology). Gn forms a heterodimeric spike complex with the Gc glycoprotein on the viral envelope, which is essential for recognizing and binding to host cell receptors, such as beta-3 integrins (Gavrilovskaya et al., 1998, Proceedings of the National Academy of Sciences). This interaction facilitates the endocytosis of the virus into the host cell, initiating the infection process. As a major surface antigen, Gn is the primary target for the host's neutralizing antibody response and is a focal point for the development of vaccines and therapeutic monoclonal antibodies (Hepojoki et al., 2010, Journal of General Virology). Targeting Gn aims to block the initial stages of the viral life cycle, preventing the systemic infection that leads to renal dysfunction and hemorrhagic symptoms. Current research focuses on identifying conserved epitopes within Gn to develop broad-spectrum hantavirus therapeutics and to mitigate the risk of antibody-dependent enhancement (Tischler et al., 2005, Virology).

Other names
G1 glycoproteinEnvelope glycoprotein GnPUUV GnPuumala orthohantavirus Gn protein
02

Mechanism of action

Neutralization of viral entry by binding to the Gn glycoprotein, thereby sterically hindering receptor interaction with host beta-3 integrins or preventing necessary conformational changes for membrane fusion (Kraus et al., 2005, Journal of Virology).

03

Biological functions

Viral attachmentReceptor bindingViral entryViral assemblyHost-cell interaction
04

Disease associations

Nephropathia epidemicaHemorrhagic fever with renal syndrome (HFRS)Infection
05

Safety considerations

Antibody-dependent enhancement (ADE)High genetic variability among PUUV strains leading to immune escapePotential for cross-reactivity with other hantaviruses
06

Interacting drugs

Experimental neutralizing monoclonal antibodies (e.g., 4G2, 1C12)

1 more in the full profile.

07

Biomarkers

Anti-Gn IgM antibodiesAnti-Gn IgG antibodiesPUUV RNA (RT-PCR)

Beyond the preview

Go deeper on Puumala virus Gn glycoprotein (Gn).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Puumala virus Gn glycoprotein (Gn).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call